期刊文献+

系统性红斑狼疮合并肺动脉高压的临床相关因素分析 被引量:4

Research on related clinical factors in patients with systemic lupus erythematosus complicated with pulmonary arterial hypertension
暂未订购
导出
摘要 目的探讨系统性红斑狼疮(SLE)患者易合并肺动脉高压的相关临床因素。方法37例SLE合并肺动脉高压的患者作为病例组,78例诊断为SLE而无合并肺动脉高压的患者为对照组。采用病例1对照研究的方法,对各个研究因素采用逐步引入一剔除法,建立Logistic回归模型。结果多因素Logistic回归分析显示,SLE患者易发生肺动脉高压的独立危险因素包括雷诺现象、疾病活动、心悸气促症状、心包积液。结论雷诺现象、疾病活动、心悸气促症状、心包积液是SLE患者易并发肺动脉高压的独立危险因素,对于这4个指标阳性的患者要尽早进行心脏彩色多普勒检查,以进行早期诊断。 Objective To investigate the related clinical factors of pulmonary arterial hypertension (PAH) patients complicated with systemic lupus erythematosus ( SLE ). Methods Thirty seven cases of patients diagnosed SLE complicated with PAH, and seventy eight cases of patients diagnosed SLE without PAH were enrolled. A case-control study was retrospectively analyzed among two groups. A logistic regression model was established. Results Muhivariates analysis showed that Raynaad's phenomenon, SLE activity, palpitations and shortness of breath, pericardial effusion were significantly associated with the happening of PAH in SLE patients. Conclusion Raynaud's phenomenon, SLE activity, palpitations and shortness of breath, pericardial effusion are the independent risk factors to SLE patients with PAIl. SLE patients with the above four factors need to undergo Doppler echocardiography examination in order to detect PAH earlier.
出处 《国际内科学杂志》 CAS 2009年第1期9-11,F0003,共4页 International Journal of Internal Medicine
基金 广东省科技计划项目(2007B031500007) 广东省医学科研基金项目(A2006192)
关键词 系统性红斑狼疮 肺动脉高压 病例-对照研究 Systemic lupus erythematosus Pulmonary arterial hypertension Case-control study
  • 相关文献

参考文献7

  • 1杨晓帆,张春兵,季晓辉.SLE患者外周血CD4^+CD25^+调节性T细胞细胞因子分泌的改变[J].国际内科学杂志,2007,34(12):685-687. 被引量:4
  • 2徐安平,梁艳仪,吕军,李劲高,宛霞,赖德源,黄湖辉.系统性红斑狼疮与CD19基因多态性的相关性研究[J].国际内科学杂志,2007,34(10):562-566. 被引量:2
  • 3Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of puhnonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 2004, 25(24) :2243-2278.
  • 4Winslow TM, Ossipov MA, Fazio GP, et al. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J,1995. 129(3) :510-515.
  • 5Haas C. Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med, 2004, 188 (6) : 985 -997.
  • 6Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J, 2003, 22 (2) :358-363.
  • 7Dorfmuller P, Zarka V, Durand-Gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med, 2002, 165(4) :534-539.

二级参考文献23

  • 1董丹丹,贺永文.CD4^+CD25^+T细胞——一种新发现的免疫调节细胞[J].国外医学(内科学分册),2006,33(5):209-214. 被引量:4
  • 2Kuroki K,Tsuchiya N,Tsao BP,et al. Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese. Genes Immun, 2002,3 ( Suppl 1 ) : S21 -S30.
  • 3Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982,25( 11 ) :1271-1277.
  • 4Thunberg U, Gidlof C, Banghagen M, et al. Hpa U polymerase chain reaction restriction fragment length polymorphism in the human CD19 gene on 16p11. Hum Hered, 1998,48 (4) :230-231.
  • 5de Rie MA, Schumacher TN, van Schijndel GM, et al. Regulatory role of CD19 molecules in B-cell activation and differentiation . Cell Immunol, 1989, 118 ( 2 ) : 368- 381.
  • 6Sato S, Steeber DA,Jpensen PJ, et al. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J Immunol, 1997,158 (10) :4662-4669.
  • 7Sato S,Ono N. Steeber DA, et al. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol, 1996, 157 (10) :4371-4378.
  • 8Sato S, Miller AS, Howard MC, et al. Regulation of B lymphocyte development and activation hv the CDI9/CD21/CD81/ Leul3 complex requires the cytoplasmic domain of CD19. J Immunol, 1997,159 ( 7 ) :3278-3287.
  • 9Sato S, Hasegawa M, Fujimoto M,et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol,2000. 165 ( 11 ) :6635-6643.
  • 10Tedder TF,Inaoki M,Sato S. The CDI9-CD21 complex regulates signal transduetion thresholds governing humoral immunity and autoimmunitv. Immunity, 1997,6 ( 2 ) : 107-118.

共引文献3

同被引文献34

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部